

THE EPIDEMIOLOGICAL CHARACTERISTICS OF HOSPITAL INFECTIONS CAUSED BY THE BACTERIA *CLOSTRIDIUM DIFFICILE* AT THE UNIVERSITY CLINICAL CENTRE OF NIŠ

Bojan Stanojević¹, Nikola Milenković¹, Sonja Novak¹, Ivica Grozdanović², Goran Maksić³

¹University Clinical Center Niš, Infectious Diseases Clinic, Niš, Serbia

²Military hospital Niš, Niš, Serbia

³University of Niš, Faculty of Medicine, doctoral studies, Niš, Serbia

Abstract:

Hospital (nosocomial, hospital-acquired) infections represent the greatest health challenge in more developed countries worldwide. Infections caused by the bacteria *Clostridium difficile* have been a serious medical problem for years. Despite the constant progress and improvement of diagnostic and therapeutic procedures, they still represent one of the most frequent and most severe hospital-acquired infections, and their incidence rate, mortality rate, as well as the severity of their clinical picture are all on the rise. This paper aims to analyse the epidemiological situations surrounding hospital-acquired infections caused by the bacteria *Clostridium difficile* at the University Clinical Centre of Niš between 2015 and 2019. In this study, *Clostridium difficile* was the most frequent cause of hospital-acquired infections of the gastrointestinal system and has been identified in as many as 48% of the studied samples. Preventive measures to control the spread of *Clostridium difficile* in a hospital environment are based on identifying transmission routes. In 1995, the first prevention and control guidelines were issued, while the Center for Disease Control and Prevention in Atlanta (CDC) modified the guidelines to control the spread of *Clostridium difficile* in health facilities, which were reevaluated in 2005, while hygiene guidelines following contact with a patient infected with *Clostridium difficile* were added. The European Centre for Disease Prevention and Control – ECDC published a new set of guidelines in 2008, while SHEA and IDSA published the most recent set of guidelines in 2010. Comprehensive examination into the interplay of different aspects of important factors dealing with *C. difficile* would provide a more detailed understanding of the various factors that could inform academics and practitioners and improve theoretical knowledge and actual practices in this really important area of public health. In that sense, the study of potential and significant factors which could have significant impact on the health of the population, especially illnesses caused by the bacteria *C. difficile* in a hospital environment should be an imperative in the scientific and professional sphere.

Key words: Hospital-acquired infections, *Clostridium difficile*, disease prevention and control

EPIDEMIOLOŠKE KARAKTERISTIKE BOLNIČKIH INFEKCIJA IZAZVANIH BAKTERIJOM *CLOSTRIDIUM DIFFICILE* U UNIVERZITETSKOM KLINIČKOM CENTRU NIŠ

Bojan Stanojević¹, Nikola Milenković¹, Sonja Novak¹, Ivica Grozdanović², Goran Maksić³

¹Univerzitetski klinički centar Niš, Klinika za infektivne bolesti, Niš, Srbija

²Vojna bolnica Niš, Niš, Srbija

³Univerzitet u Nišu, Medicinski fakultet, student doktorskih studija, Niš, Srbija

Bolničke (nozokomijalne, intrahospitalne) infekcije predstavljaju najveći zdravstveni izazov u razvijenim zemljama sveta. Infekcije izazvane bakterijom *Clostridium difficile* predstavljaju ozbiljan medicinski problem godinama unazad. I pored konstantnog napredovanja i usavršavanja dijagnostičkih i terapijskih procedura, još uvek predstavlja jednu od najčešćih i najtežih infekcija stečenih u bolničkoj sredini, a u porastu su incidencija, obolevanje, smrtnost kao i težina kliničke slike. Cilj ovog rada je sagledavanje epidemiološke situacije bolničkih infekcija izazvanih bakterijom *Clostridium difficile* u UKC Niš u periodu od 2015-2019. godine. U ovom istraživanju, *Clostridium difficile* je bio najčešći uzročnik bolničkih infekcija gastrointestinalnog sistema i dokazan je u čak 48% ispitanih uzoraka. Mere sprečavanja širenja *Clostridium difficile*-a u bolničkoj sredini zasnivaju se na poznavanju puteva prenošenja. 1995. godine pripremljene su prve preporuke za prevenciju i kontrolu, a Centri za prevenciju i kontrolu bolesti u Atlanti (CDC) su ublikovali preporuke za prevenciju širenja *Clostridium difficile*-a u zdravstvenim ustanovama koje su obnovljene 2005. godine, a dodate su i preporuke za higijenu ruku posle kontakta sa bolesnikom sa *Clostridium difficile*. Evropski centar za prevenciju i kontrolu bolesti (European Centre for Disease Prevention and Control – ECDC) publikovao je 2008. nove preporuke, a 2010. godine SHEA i IDSA izdali su najnovije preporuke. Sveobuhvatna istraživanja i objašnjenja vezana za međusobne odnose različitih aspekata važnih za borbu sa efektima prouzrokovanim *Clostridium difficile*-a mogu da pruže bolje i jasnije razumevanje različitih faktora koji su značajni sa unapređenje znanja i kod pripadnika akademske zajednice ali i kod profesionalaca u praksi te tako mogu jačati i teorijska saznanja i načine reagovanja praksi u ozbiljno značajnoj oblasti javnog zdravlja. U tom smeru, studije vezane za potencijalne i značajne faktore koji imaju uticaj na zdravlje ljudi, posebno oboljenja prouzrokovana bakterijom *Clostridium difficile* u bolničkim uslovima trebaju da budu neka vrsta imperativa kako u naučnoj sferi tako i medicinskoj praksi.

Ključne reči: intrahospitalne infekcije, *Clostridium difficile*, prevencija i kontrola bolesti

Introduction

Hospital (nosocomial, hospital-acquired) infections (HIs) represent the greatest health challenge in the developed countries of the world. They include infections contracted both by the patients and staff in hospitals or in some other health facilities. They can manifest as a local or a systemic illness (conditions) which represents the body's response to the presence of an infective agent (one or more) or its toxins, not found in the patient, when the patient was not in an incubation period prior to admission to the hospital or some other health institution (1,2,3).

Despite the considerable progress in the development of medicine, as well as the progress made in further developing hospital epidemiology, according to the World Health Organization (WHO), hospital-acquired infections are to this day a global problem which considerably increases overall morbidity and mortality, lengthens treatment time, and increases the overall cost of healthcare. The spread of multi-drug resistant pathogen bacteria is a particular problem, as is the transmission of infections onto healthcare workers and into the environment (4, 5).

Infections caused by the *Clostridium difficile* (*C. difficile*) bacteria have been a serious medical problem for years. Despite the constant progress and improvement of diagnostic and therapeutic procedures, they still represent one of the most frequent and most severe hospital-acquired infections, and their incidence rate, mortality rate, as well as the severity of the clinical picture of a *C. difficile* infection (CDI) are all on the rise. (5, 6). *C. difficile* can normally be found among 3% of the adult population, while the carriage of this bacteria in the digestive tract of hospitalized patients is much higher and reaches up to 21% (8, 9).

This paper aims to view the epidemiological situations related to hospital-acquired infections caused by the bacteria *C. difficile* at the University Clinical Centre of Nis from 2015 to 2019. By determining the basic epidemiological characteristics, we obtained the necessary elements to form guidelines for the measures and procedures aimed at preventing and controlling hospital-acquired infections caused by these bacteria at the University Clinical Centre of Nis.

Material and methods

This paper includes data from the archives of the Institute of Public Health Nis, the Centre for Disease Control and Prevention, as well as reports of the Department of Sanitary and Epidemiological Supervision of the University Clinical Centre of Nis including: reports on trends in nosocomial infections caused by the bacteria *C. difficile* at the University Clinical Centre of Nis from 2015 to 2019; reports on trends in nosocomial infections caused by the bacteria *C. difficile*; reports on patients hospitalized at the University Clinical Centre of Nis.

A descriptive method was used to analyse the data. All the data were statistically processed using Microsoft Office and Excel (version 2019).

The results

The University Clinical Centre of Nis consists of 36 organized units (OU) of which 14 OUs are clinics of particular surgical branches. In 2018, the General Surgery Clinic was reorganized and the following clinics formed: the Abdominal Surgery Clinic, Endocrine Surgery and Breast Surgery Clinic, Vascular Surgery Clinic, Digestive Surgery Clinic, and as a special unit, the Anaesthesiology and Intensive Therapy Clinic.

The data analysis is shown in Table 1, and based on it we can conclude that in 2015 most HIs caused by the bacteria *C. difficile* were reported at the Physical Medicine and Rehabilitation Clinic (16) and the Gynaecology and Obstetrics Clinic (15), with the highest incidence rate reported at the Physical Medicine and Rehabilitation Clinic (14.16%) and the Urology Clinic (10.68%). The Endocrinology, Haematology, Infectious Disease Clinics, as well as the Vascular, Cardiology, and Paediatric Surgery Clinics had no instances of infections caused by the bacteria *C. difficile* (Table 1).

Table 1. The number of findings and the incidence rate of HI caused by the bacteria *Clostridium difficile* from 2015 to 2019

CLINIC	The number of findings/ incidence rate for 2015	The number of findings/ incidence rate for 2016	The number of findings/ incidence rate for 2017	The number of findings/ incidence rate for 2018	The number of findings/ incidence rate for 2019
CARDIOLOGY	6/1.13	12/2.31	6/1.13	1/0.18	2/0.35
GASTROENTEROLOGY AND HEPATOLOGY	6/2.52	8/3.32	2/0.93	2/1.07	2/1.08
ENDOCRINOLOGY	0.00	0.00	1/0.80	0.00	0.00
HAEMATOLOGY	0.00	0.00	1/0.88	0.00	0.00
NEPHROLOGY	10/9.16	0.00	8/7.92	1/1.00	7/5.87
ONCOLOGY	2/0.69	0.00	0.00	0.00	0.00
INFECTIOUS DISEASE	0.00	0.00	4/3.82	2/2.18	4/5.27
PEDIATRIC	3/0.37	0.00	0.00	0.00	0.00
PULMOLOGY	3/1.13	3/1.16	1/0.41	0.00	2/1.43
NEUROLOGY	10/5.28	0.00	6/3.39	0.00	0.00
REHABILITATION	16/14.16	6/5.38	3/2.91	1/0.94	5/4.94
GENERAL SURGERY	10/3.37	2/0.66	2/0.67	0.00	0.00
NEUROSURGERY	13/8.80	3/2.01	8/..	10/6.39	4/2.33
ORTHOPEDIC	3/1.46	2/1.02	4/2.03	0.00	1/0.49
UROLOGY	10/10.68	8/4.20	3/1.74	0.00	3/1.61
VASCULAR SURGERY	0.00	0.00	0.00	0.00	1/2.13
PLASTIC SURGERY	2/2.27	3/3.75	1/1.03	0.00	0.00
CARDIOSURGERY	0.00	5/3.56	10/7.69	1/1.22	1/2.34
GYNAECOLOGY	15/2.28	0.00	6/0.85	0.00	1/0.15
PEDIATRIC SURGERY	0.00	0.00	0.00	0.00	0.00
EMERGENCY AND THORACIC SURGERY	2/1.75	4/2.63	1/0.72	1/1.77	1/1.36

In 2016, most hospital-acquired infections caused by *C. difficile* were reported at the Cardiology Clinic (12), while the highest incidence rate was reported at the Physical Medicine and Rehabilitation Clinic (5.38%). The Endocrinology, Haematology, Nephrology, Oncology, Infectious Disease, Paediatric, Gynaecology, as well as the Vascular and Paediatric Surgery Clinics had no instances of hospital-acquired infections caused by the bacteria *C. difficile*.

In 2017, the greatest number of HIs caused by the bacteria *C. difficile* were reported at the Cardiovascular Surgery Clinic (10) and the Nephrology and Neurosurgery Clinics (8). The highest incidence rate for that year was reported at these clinics. The Oncology and Paediatric Clinics, as well as the Vascular and Paediatric Surgery Clinics had no infections caused by the bacteria *C. difficile*.

Based on the analysis of data from 2018, most of the HIs caused by the bacteria *C. difficile* originated from the Neurosurgery Clinic (10), which had the highest noted incidence rate (6.39%). At the remaining clinics, a significantly lower number of incidences were noted.

Finally, in 2019, most of the HIs caused by the bacteria *C. difficile* were reported at the Nephrology Clinic (7), which also had the highest incidence rate (5.87%). At the Endocrinology, Haematology, Paediatric, Oncology, and Neurology Clinics, as well as the Vascular and Paediatric Surgery Clinics, no hospital-acquired infections caused by the bacteria *C. difficile* were reported.

AMM Paper Accepted

Epidemics at the University Clinical Centre of Nis

From 2015 to 2019, there were several epidemics at the University Clinical Centre of Nis, two of which were epidemics in the operating theatres, in 2015 and 2016, at the General Surgery Clinic.

An epidemic caused by the bacteria *Clostridium difficile* at the Neurosurgery Clinic of the University Clinical Centre of Nis in 2015

A hospital epidemic caused by the bacteria *C. difficile* at the Neurosurgery Clinic of the University Clinical Centre of Nis was declared on April 28, 2015. An epidemiological study determined that the epidemic began on April 22, 2015 when three patients contracted the infection (two female and one male). The number of exposed patients and health workers totalled 95. Following adequate and rapid implementation of measures, the spread of the bacteria in hospital conditions was prevented and the epidemic was called off on May 6, 2015. There were no casualties.

The source of the contagion was not determined. The patients exhibited the following clinical symptoms: watery stools, weakness, fatigue. The proposed measures to control the epidemic were: reporting the epidemic, reporting the infected patients, epidemiological testing, and isolation of the infected; acquiring stool samples from all the exposed patients for laboratory analysis; spatial and personal isolation; heightened measures of general and personal hygiene of the patients and staff; more frequent cleaning of the wards with bleach-based chemical products; the use of gloves and single-use lab coats (PVC aprons); reduced visits; prohibiting outside food intake; as needed, consulting with an infectious disease specialist; health-related and educational work with everyone involved.

An epidemic caused by the bacteria *Clostridium difficile* at the Neurology Clinic of the University Clinical Centre of Nis in 2015

A hospital epidemic caused by the bacteria *C. difficile* at for Neurology Clinic of the University Clinical Centre of Nis was declared on July 14, 2015. Through an epidemiological analysis it was determined that the epidemic broke out on June 24, 2015 when three patients became infected (one female and two male). The number of exposed patients and healthcare workers amounted to 57. After adequate and rapidly implemented measures, the spread of the bacteria in hospital conditions was stopped and the epidemic was called off on July 28, 2015. There were no casualties.

The source of the contagion was not determined. The patients had the following clinical symptoms: watery stools, weakness, fatigue. The proposed measures to control the epidemic covered the following steps: reporting the epidemic; reporting the infected patients; epidemiological testing and isolation of the infected; acquiring stool samples from all the exposed patients for laboratory analysis; spatial and personal isolation; heightened measures of general and personal hygiene of the patients and the staff; more frequent cleaning of the wards with bleach-based chemical products; the use of gloves and single-use lab coats (PVC aprons); reduced visits; prohibiting outside food intake; as needed, consulting with an infectious disease specialist; health-related and educational work with everyone involved.

Discussion

The problem of hospital infections emerged with the introduction of hospital treatment. Little was known about the causes and means of transmission of HIs, and virtually nothing was known about disinfection, sterilization, and aseptic techniques (10, 11, 12). The work of Ignaz Philipp Semmelweis provided significant progress in that respect, and remains an example of the importance of epidemiology in the prevention and control of HIs a full decade before the microbiological discoveries of Pasteur and Koch. Specifically, Semmelweis noted the

difference in the maternal mortality rate in two different clinics of the maternity ward of the University Hospital in Vienna. A higher maternal mortality rate was registered at the clinic which was part of the university hospital, where the doctors and students often, straight from performing autopsies, without previous preparations, took part in deliveries (Figure 1) (13, 14). At the clinic with a lower maternal mortality rate, the midwives were in charge of the births. After implementing Semmelweis's guidelines on hand hygiene (hand disinfection using calcium hypochlorite), the maternal mortality rate was reduced significantly in both clinics, in the one that was part of the university hospital by 89%, and the one run by midwives by 52% (15, 16).




Figure 1. The maternal mortality rate due to infection at the University Hospital in Vienna, Austria, 1841-1850 (7)

All this is an indication that infections caused by the bacteria *C. difficile* have been a serious medical problem for years, especially when it comes to hospital-acquired infections. Considerable efforts have been invested into developing and improving national health strategies, considering that it is known that the quickest means of transmission is through direct contact with the source of the contagion or indirect contact involving the hands of the staff or contaminated medical equipment. It is estimated that at least 20% of HIs can be prevented by implementing specific means of supervision and control. In order to increase the quality of healthcare and the safety of the patients, it is necessary to gain as detailed an insight as possible

into the nature and scope of the existing problem. Precisely because of that, epidemiological and micro-biological studies of these infections are more than welcome. Their implementation is considerably advocated for and supported by European and American associations (the CDC, ECDC, ECMID). Thus, this study too was carried out in accordance with their guidelines and with the desire to improve the quality of healthcare at the University Clinical Centre of Nis.

In this study, *C. difficile* was the most frequent cause of hospital-acquired infections of the gastro-intestinal system and it was identified in as many as 48% of the studied samples. Great differences were noted in the prevalence of HA-CDIs among various countries, which is a consequence of the varying frequency of testing, as well as the varying sensitivity and the specific nature of the diagnostic tests. This is probably a result of a lack of funding but also diagnostic guidelines. Even though numerous European countries have developed regional and/or national networks for reporting CDIs, based on the data provided by the European Commission, monitoring is not standardized or legally binding in all European countries (17, 18, 19, 20, 21, 22).

In order for *C. difficile* to cause diarrhoea, at least three conditions need to be met: a change in the normal ratio of bacteria inhabiting the digestive tract, the production of the *C. difficile* toxin, and particular characteristics on the part of the host. Normal intestinal flora among adults usually prevents the onset of colonies of *C. difficile*. *C. difficile* secretes two main toxins: enterotoxin (toxin A) and cytotoxin (toxin B). Previously, it was considered that the strain which only secretes toxin B (A-/B+) cannot cause damage to the mucus tissue of the colon. However, recent studies have shown that toxin B is the main determinant in the virulence and that avirulent strains only secrete toxin A (23,24). Kuehne et al. (25,26), based on a genetic analysis, determined that the production of one or both toxins indicates cytotoxin activity both *in vitro* and *in vivo*, so that the current hypothesis regarding the importance of both toxins for the onset of the illness has been adopted. Research done in referent laboratories for anaerobic infections of the Institute of Public Health Nis in 2014 resulted in the first isolates of *C. difficile*

from 175 samples taken from the environment (23, 24, 27). In soil samples from within the University Clinical Centre of Nis, the parks in the city of Nis, and mud and sand samples from unregulated sewer systems in the municipality of Niska banja, small numbers of the *C. difficile* bacteria which produce toxins (A+B+) as well as non-toxigenic isolates (A-B-) were registered. The role of the third toxin, known as the binary toxin, has still not been sufficiently studied, even though it caused epidemics associated with a very serious clinical picture (24, 28, 32). The *C. difficile* ribotype 027 which is toxin A-positive and toxin B-positive also has a gene for a binary toxin, as well as a 18bp deletion and a mutation on the *tcdC* gene, leading to a disruption in the expression of toxins A and B. This strain leads to the considerable production of the toxin *in vitro* and is particularly important as it is resistant to fluoroquinolones. A study carried out in 38 hospitals from 14 European countries indicated that the prevalence of the epidemic-inducing 027 strain of *C. difficile* was 6.2%, that all the strains were positive for the binary toxin, resistant to erythromycin and moxifloxacin but also sensitive to metronidazole and vancomycin. However, the infected patients had a much more severe form of the illness (29). The model of origin of the CDI is as follows: patients are admitted to the hospital, and although intermittently exposed to spores of *C. difficile* they have a negligible risk of the occurrence of the condition until the application of antibiotics. After they have been included, especially when it comes to broad-spectrum penicillins, cephalosporins, and clindamycins, the normal intestinal flora is disrupted, so that when *C. difficile* enters the digestive tract of such patients, it can proliferate and colonize the mucus tissue without causing any kind of symptoms of the illness (asymptomatic colonization), in the case of a strain which does not secrete toxins or a strain which secretes toxins but where an immunological response has been activated through the secretion of IgG. However, if there is no immunological response, symptomatic conditions will occur (30, 31, 32).

A high rate of possible carriage persists over the first 8 months of life, until normal intestinal flora is achieved, and then it decreases to about 2-3% among adults. A study carried

out in Sweden indicated a carriage rate of 1.9% in the case of 594 volunteers, while Philips and Rogers (33) determined a rate of 2% after analysing 100 randomly selected stool samples, which were negative for other pathogens of the digestive tract. A special aspect of transmitting *C. difficile* is the carriage of this bacteria in the digestive tract of hospitalized patients. Carriage among hospitalized individuals is considerably higher (up to 21%) (5). In prospective studies in which the patients were systematically examined for the presence of the bacteria during patient intake and one or possibly two weeks after being admitted to hospital in western Europe, the rate of *C. difficile* carriage after a stay in hospital ranged from 5.9 to 11%. This is a much higher rate than the 3% which occurs among the healthy adult population and could be a consequence of using antibiotics or colonisation during previous hospitalizations. A study carried out in Nis also indicated a higher carriage rate of *C. difficile* among hospitalized patients (7%), and also of the presence of toxigenic strains in the intestine of 2% of hospitalized patients with a formed stool (34).

The incidence rates of CDIs vary depending on the type of hospital, country, and time of analysis. In all of Northern America the incidence rate has been on the rise over the past fifteen years, despite preventive measures, with the highest noted in university hospitals. Over the past decade, the number of those infected has doubled (35, 36). In a prevalence study carried out in 2008 in 648 hospitals in the USA, it was determined that 13 out of 1.000 hospitalized patients (1.3%) were suffering from CDIs or were colonised (37, 38). That is a higher rate than was previously predicted. This considerable increase can be ascribed to the occurrence of a very virulent ribotype 027 (NAP1/HI/27) which caused major epidemics in the USA and Canada from 2001 to 2003 (39, 40, 41, 42). Even though the increase in the incidence rate can be a reflection of improved diagnostics and the identification of this condition, it is still clear that the incidence rate has actually increased. In Europe, the incidence rates also vary by country and hospital. It was recently estimated that the average incident rate in Europe was 4.1 for every 10.000 hospitalized patients. It is important to note that, after many epidemics which were

caused by ribotype 027, other ribotypes of *C. difficile* are now also prevalent in Europe. In a large-scale study which included data from 106 laboratories from 34 European countries (the aim was to compile data from at least one hospital in each country with a population of fewer than two million citizens, three hospitals in the case of two to twenty million citizens, and five hospitals in the case of more than twenty million citizens), according to the latest published data for November 2008, the most frequent ribotypes were 014 and 020 (identified in 19 countries), then 001 (in 13 countries), and 078 (in 18 countries). The PCR-ribotype 027 is sixth in terms of frequency of occurrence (41, 42). Few data exist on the frequency of occurrence of CDIs in the countries of South-East Europe. In the cited study for Europe, there are data for Bulgaria, Croatia, Slovenia, and Greece. The average incidence rate of hospital-acquired infections related to *C. difficile* range from three per 10.000 hospitalized patients in Bulgaria, six in Croatia, 19 in Slovenia and 29 in Greece (42, 44). In a study carried out during 2008 in Nis, in 12.4% of clinical stool samples obtained from patients experiencing diarrhoea, a cause was isolated. Of the overall number of positive isolates (351), *C. difficile* was isolated in 27.1% (45).

Even though most of the patients with CDIs are hospitalized, this condition should not be linked to medical interventions, since it can also occur in institutions for long-term care, housing for the elderly, and also in day hospitals. A reservoir could also be colonised (asymptomatic) or ill patients and the hospital environment. When cases of CDAD are noted in a health institution, that there are also numerous asymptomatic carriers in the same room, or on the same ward, should also be taken into consideration, as they represent a significant source of hospital diarrhoea. Still, routine screening is still not recommended as a preventive measure. All surfaces and objects contaminated by spores of *C. difficile* (the floor, furniture, medical equipment) are also a significant reservoir. The rate of contamination usually correlates with the epidemic nature of the illness.

According to the results of a study of European countries, the risk factors for older age patients (approximately two-thirds of those infected were over the age of 65), the presence of serious comorbidities and antibiotic therapy were considered risk factors. Almost all the patients who took antibiotics for three months prior to a *C. difficile* infection, usually received cephalosporins, quinolones, and beta lactamase inhibitors (28). Almost all the antibiotics administered either orally or parenterally can be linked to CDIs. The first antibiotic linked to this illness was clindamycin. More recent studies indicate that this illness is linked to therapy involving cephalosporins and fluoroquinolones (45, 46). The more recent occurrence of the resistance of *C. difficile* to fluoroquinolones is linked to their broad application (45, 46). Ceftriaxone is especially marked as an antibiotic that disrupts normal gastrointestinal flora, and has no effect on *C. difficile* itself, which promotes the occurrence of CDIs during its use in the recovery stage of intestinal flora. However, not all patients taking antibiotics will develop a CDI as well. What is also important is the ability of the immune system to produce the serum IgG anti-toxin A. This explains why CDIs are more frequent among the elderly. It should be mentioned that using more antibiotics at the same time is linked to the higher risk of occurrence of a CDI (42, 45).

The incidence rate of CDADs varies and ranges from 0.1 to 2% (47, 48, 49, 50, 51). This incidence rate includes patients who are hospitalized due to a *C. difficile* infection, as well as patients with a hospital-acquired *C. difficile* infection. Most researchers agree that the infections caused by *C. difficile* occur in a hospital environment. Insufficient attention is paid to the role and prevalence of *C. difficile* as the cause of diarrhoea in non-hospital environments.

Measures aimed at preventing the spread of *C. difficile* in hospital environments depend on the identification of transmission routes. Back in 1995 the first guidelines for the prevention and control of CDIs were provided. The CDC in Atlanta published guidelines for the prevention and control of *C. difficile* in healthcare facilities which were renewed in 2005, and recommendations for hand hygiene following contact with a patient with a CDI were added

(52, 53, 54). The European Centre for Disease Prevention and Control – ECDC published new guidelines in 2008, while SHEA and IDSA published the most recent set of guidelines in 2010 (55, 56, 57).

Conclusion

Illnesses caused by the bacteria *C. difficile* in a hospital environment represents a great challenge for modern-day medicine. An increase in the number of more severe cases and the irresponsible use of antibiotics are the main factors which contribute to their spreading. Healthcare workers and health service providers are facing the important task of adopting suitable and proven preventive measures and, where necessary, therapeutic measures, so that the spread of an illnesses caused by *C. difficile* could fully be brought under control. Comprehensive examination into the interplay of different aspects of important factors dealing with *C. difficile* would provide a more detailed understanding of the various factors that could inform academics and practitioners and improve theoretical knowledge and actual practices in this really important area of public health. In that sense, the study of potential and significant factors which could have significant impact on the health of the population, especially illnesses caused by the bacteria *C. difficile* in a hospital environment should be an imperative in the scientific and professional sphere.

References

1. Šuljagić V, Denić Lj. Bolničke infekcije – problem savremene medicine. Vojnosanitetski preglad. 2005 July. Military-medical and pharmaceutical review 62(7-8):569-573.
2. Melariri H, Freercks R, van der Merwe E. The burden of hospital-acquired infections (HAI) in sub-Saharan Africa: a systematic review and meta-analysis. *E Clinica lMedicine* 2024; 71:1025-41. doi:10.1016/j.eclinm.2024.102541.
3. Mitra, M, Ghosh A, Pal R, Basu M. Prevention of hospital-acquired infections: A construct during Covid-19 pandemic. *Journal of Family Medicine and Primary Car* 2021; 10(9): 3348-54, DOI: 10.4103/jfmmpc.jfmmpc_742_21.
4. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988; 16(3): 128-40.
5. Tchouaket E, Beogo I, Sia D, K. Kilpatrick K, C. Séguin C, A. Baillet A, et al. Economic analysis of healthcare-associated infection prevention and control interventions in medical and surgical units: systematic review using a discounting approach. *Journal of Hospital Infection* 2020; 106(1): 134-54, <https://doi.org/10.1016/j.jhin.2020.07.004>.
6. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing *Clostridium difficile*-infection (CDI). *Clin Microbiol Infect* 2009;15:1053-66.
7. Bauer MP, Noretmans DW, van Benthem BH i sur. *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet* 2011;377:63-73.
8. Delmee M, Vandercam B, Avesani V. Epidemiology and prevention of *Clostridium difficile* infection in leukemia unit. *Eur J Clin Microbiol* 1987; 6: 623-7.
9. Markantonis JE, Fallon JT, Madan R, Alam MZ. *Clostridioides difficile* Infection: Diagnosis and Treatment. *Challenges. Pathogens.* 2024; 13(2):118. <https://doi.org/10.3390/pathogens13020118>
10. Kucurski Lj, Baković B. Bolničke infekcije – znanja, stavovi i informisanost učenika i studenata zdravstvenog smjera. Biomedicinska istraživanja. 2017 July. Biomedicinska istraživanja 8(1); DOI: 10.7251/BII1701063K.
11. Principi N, Gnocchi M, Gagliardi M, Argentiero A, Neglia C, Esposito S. (2020). Prevention of *Clostridium difficile* Infection and Associated Diarrhea: An Unsolved Problem. *Microorganisms* 2020, 8(11): 1640-55. <https://doi.org/10.3390/microorganisms8111640>
12. Doll M, Marra R, Anucha Apisarnthanarak A, Amal SA, Abbas S, Rosenthal VD. Prevention of *Clostridioides difficile* in hospitals: A position paper of the International Society for Infectious Diseases. *International Journal of Infectious Diseases* 2021; 102: 188-95 doi.org/10.1016/j.ijid.2020.10.039.

13. Latham, R. (2000). CG Mayhall, ed; Hospital Epidemiology and Infection Control, 2nd ed Lippincott Williams & Wilkins, 1999; 1,560 pages. Infection Control & Hospital Epidemiology, 21(4), 285-286. doi:10.1017/S0195941700054898
14. Stang A, Standl F, Poole C. A twenty-first century perspective on concepts of modern epidemiology in Ignaz Philipp Semmelweis' work on puerperal sepsis. Eur J Epidemiol. 2022; 37(5):437-445. doi:10.1007/s10654-022-00871-8.
15. Fratarić I. Semmelweis's hypothesis: Almost 150 years since Ignac Fulop Semmelweis passed away. Timočki medicinski glasnik. 2014 January. Timočki medicinski glasnik 39(1): 44-49; DOI: 10.5937/tmg1401044F.
16. Kadar, N. Rediscovering Ignaz Philipp Semmelweis (1818–1865), American Journal of Obstetrics and Gynecology. 2019; 220(1): 26-39, doi.org/10.1016/j.ajog.2018.11.1084.
17. European Commission. 2012. Commission staff working document: Detailed analysis of countries' reports on the implementation of the Council Recommendation (2009/C151/01) on patient safety, including the prevention and control of healthcare associated infections SWD (2012) 366 final. Brussels, EU.
18. Suetens C. *Clostridium difficile*: summary of actions in the European Union. Eurosurveillance. 2008;13:1-2.
19. Barbut F, Jones G, Eckert C. Epidemiology and control of *Clostridium difficile* infections in healthcare settings: an update. Curr Opin Infect Dis 2011;24:370-6.
20. Liu C, Monaghan T, Yadegar A, Louie T, Kao D. Insights into the Evolving Epidemiology of *Clostridioides difficile* Infection and Treatment: A Global Perspective. Antibiotics 2023; 12(7), 1141-55. <https://doi.org/10.3390/antibiotics12071141>
21. Vehreschild MJGT, Schreiber S, von Müller L et al. Trends in the epidemiology of *Clostridioides difficile* infection in Germany. Infection 2023; 51: 1695–1702. <https://doi.org/10.1007/s15010-023-02044-5>.
22. European Centre for Disease Prevention and Control. *Clostridioides difficile* infections. In: ECDC. Annual epidemiological report for 2018–2020. Stockholm: ECDC; 2024.
23. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. N Engl J Med 1989; 320: 204–10.
24. Markantonis JE, Fallon JT, Madan R, Alam MZ. *Clostridioides difficile* Infection: Diagnosis and Treatment Challenges. Pathogen. 2024; 13(2): 118-29. <https://doi.org/10.3390/pathogens13020118>

25. Barbut F, Decre D, Lalande V, et al. Clinical features of *Clostridium difficile*-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. *J Med Microbiol* 2005; 54: 181–5.
26. Vitiello A, Sabbatucci M, Zovi A, Salzano A, Ponzo A, Boccellino M. Advances in Therapeutic Strategies for the Management of *Clostridioides difficile* Infection. *Journal of Clinical Medicine* 2024; 13(5):1331. <https://doi.org/10.3390/jcm13051331>
27. Stojanovic P, Kocić B, Dragovac G, ranđelović M, Pantovic V, Mitic Z, Stojanovic K. Ten years from the introduction of *Clostridium difficile* in microbiological diagnostics in Serbia. *Acta Facultatis Medicae Naissensis* 2017; 34 (3): 235-41.
28. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* 2005; 366: 1079–84.
29. Sunenshine RH, McDonald CL. *Clostridium difficile* associated disease: new challenges from an established pathogen. *Cleve Clin J Med* 2006; 73: 187–97.
30. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolini R, de Lalla F. Prospective study of *Clostridium difficile* intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. *Antimicrob Agents Chemother* 1991; 35: 208–10.
31. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of *Clostridium difficile*-associated diarrhea among outpatients at a cancer hospital. *Infect Control Hosp Epidemiol* 2005; 26: 680–4.
32. Eeuwijk J, Ferreira G, Yarzabal JP, Robert-Du R, van Beest HMA. Systematic Literature Review on Risk Factors for and Timing of *Clostridioides difficile* Infection in the United States. *Infect Dis Ther.* 2024;13(2):273-298. doi:10.1007/s40121-024-00919-0
33. Philips K, Rogers P. Rapid detection and presumptive identification of *Clostridium difficile* by p-cresol production on a selective media. *J Clin Pathol* 1981; 34: 642-4.
34. Stojanovic P, Kocić B, Stojanovic N, Stojanovic K, Babic T, Mladenovic-Antic S. Zastupljenost toksigenih i netoksigenih izolata *Clostridium difficile* kultivisanih iz uzoraka stolice hospitalizovanih bolesnika Srbije. 7th congres of medical microbiology - Micromed 2010. Zbornik rezimea p.10.
35. Starr J. *Clostridium difficile* associated diarrhoea: diagnosis and treatment. *BMJ* 2005; 331: 498–501.
36. Zyoud SH. Global research on *Clostridium difficile*-associated diarrhoea: A visualized study. *World J Gastroenterol* 2022; 28(28):3720-3731. doi:10.3748/wjg.v28.i28.3720.

37. Monaghan T, Boswell T, Mahida YR. Recent advances in *Clostridium difficile*-associated disease. *Gu*. 2008; 57: 850–60. 19.
38. Normington C, Chilton CH, Buckley AM. *Clostridioides difficile* infections; new treatments and future perspectives. *Curr Opin Gastroenterol* 2024; 40(1):7-13. doi:10.1097/MOG.0000000000000989.
39. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic treated hospitalized patients: a prospective study. *J Antimicrob Chemother* 2001; 47: 43–50.
40. Crabtree TD, Pelletier SJ, Gleason TG, Pruett TL, Sawyer RG. Clinical characteristics and antibiotic utilization in surgical patients with *Clostridium difficile*-associated diarrhea. *Am Surg* 1999; 65: 507–11.
41. Harbarth S, Samore MH, Carmeli Y. Antibiotic prophylaxis and the risk of *Clostridium difficile*-associated diarrhoea. *J Hosp Infect* 2001; 48: 93–7.
42. Bhatawadekar SM, Yadav LS, Babu A, Modak MS. Antibiotic-Associated *Clostridium difficile* Diarrhoea in Tertiary Care Hospital – A Study from Western India. *J Pure Appl Microbiol*. 2023; 17(3):1471-76. doi: 10.22207/JPAM.17.3.08.
43. Bolton R, Tait S, Dear P. Asymptomatic neonatal colonisation by *Clostridium difficile*. *Arch Dis Child* 1984; 59: 466-72.
44. Kociulek LK, Gerding DN, Carrico R. Strategies to prevent *Clostridioides difficile* infections in acute-care hospitals: 2022 Update. *Infect Control Hosp Epidemiol*. 2023; 44(4):527-49. doi:10.1017/ice.2023.18.
45. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet* 1998;351(9103): 633–6.
46. Shen Y, Lin S, You P. Rapid discrimination between clinical *Clostridioides difficile* infection and colonization by quantitative detection of TcdB toxin using a real-time cell analysis system. *Front Microbiol*. 2024; 15: 1348-62. doi:10.3389/fmicb.2024.134889
47. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial *Clostridium difficile*-associated diarrhea in Canadian hospitals. *Infect Control Hosp Epidemiol* 2002; 23: 137–40.
48. Olson MM, Shanholtzer CJ, Lee JT, Gerding DN. Ten years of prospective *Clostridium difficile* disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-91. *Infect Control Hospital Epidemiol* 1994; 15: 371-81.

49. Bowen KE, McFarland LV, Greenberg N, Ramsey MM, Record KE, Svenson J. Isolation of *Clostridium difficile* at a University hospital: two-year study. *Clin Infect Dis* 1995; 20: 261-2.
50. Borji S, Rostamian M, Kadivar S. Prevalence of *Clostridioides difficile* contamination in the healthcare environment and instruments: A systematic review and meta-analysis. *Germs*. 2022; 12(3):361-371. doi:10.18683/germs.2022.1340.
51. Carling PC, Parry MF, Olmstead R. Environmental approaches to controlling *Clostridioides difficile* infection in healthcare settings. *Antimicrob Resist Infect Control* 2023; 12: 94-104. <https://doi.org/10.1186/s13756-023-01295-z>.
52. Tabaqchali S, Wilks M. Epidemiological aspects of infections caused by *Bacteroides fragilis* and *Clostridium difficile*. *Eur J Clin Microbiol Infect Dis* 1992; 11: 1049-57.
53. Turner NA, Krishnan J, Nelson A. CDC's Hospital-Onset *Clostridioides difficile* Prevention Framework in a Regional Hospital Network. *JAMA Netw Open* 2024; 7(3): 2438-46. doi:10.1001/jamanetworkopen.2024.3846
54. Barbut F. Epidemiology of *Clostridium difficile*-associated infections. *Clinical Microbiology and Infection* 2001; 7: 405-11.
55. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial *Clostridium difficile*-associated disease during an epidemic caused by a hypervirulent strain in Quebec. *CMAJ* 2005; 173: 1037-42.
56. European centre for disease prevention and control strategy 2021-2027. Available from: URL: <https://www.ecdc.europa.eu/sites/default/files/documents/ECDC-Strategy-2021-2027.pdf>.
57. European centre for disease prevention and control long-term surveillance framework 2021-2027 Available from: URL: <https://www.ecdc.europa.eu/sites/default/files/documents/long-term-surveillance-framework-2021-2027.pdf>.